Nutrition company dsm-firmenich’s 2024 Q3 financial data indicate an 8% organic sales growth. The company has increased its 2024 full-year outlook with an adjusted operating result (EBITDA) toward €2.1 billion (US$2.28 billion). Adjusted EBITDA increased 32% in the quarter. As the vitamin market experienced supply disruptions during the quarter, the company expects that the growth in some vitamin prices will lead to a temporary profit contribution of around €80 million (US$86.9 million) in Q4. dsm-firmenich highlights that its synergies and vitamin transformation programs are “firmly on track.”
